Cite
Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors.
MLA
Chang, Bee-Song, et al. “Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors.” Journal of Personalized Medicine, vol. 12, no. 3, Mar. 2022, p. 404–N.PAG. EBSCOhost, https://doi.org/10.3390/jpm12030404.
APA
Chang, B.-S., Peng, T.-C., Wu, Y.-F., Hsieh, T.-C., & Huang, C.-H. (2022). Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors. Journal of Personalized Medicine, 12(3), 404–N.PAG. https://doi.org/10.3390/jpm12030404
Chicago
Chang, Bee-Song, Tai-Chu Peng, Yi-Feng Wu, Tsung-Cheng Hsieh, and Chun-Hou Huang. 2022. “Prognostic Values of Inflammatory Indexes and Clinical Factors in Patients with Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma and Treated with Tyrosine Kinase Inhibitors.” Journal of Personalized Medicine 12 (3): 404–N.PAG. doi:10.3390/jpm12030404.